deucravacitinib vs zasocitinib

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Psoriasis

Shared mechanism: TYK2 · full Psoriasis pipeline

deucravacitinib · Sotyktu

Marketed by Bristol-Myers Squibb

Approved in Psoriasissmall molecule
Reliable signal

NCT03611751 · Phase 3 · completed

This was a randomized, quadruple-blind, placebo- and active-controlled trial of 1,020 participants. Both primary clinical endpoints at week 16 were met: deucravacitinib produced significantly more participants with sPGA 0/1 and PASI 75 responses than placebo.

Next expected readout: November 2026 · NCT05570955 (registry estimate)

Reported efficacy

The Percentage of Participants With sPGA Response of 0 or 1 (At week 16); The Percentage of Participants With PASI 75 Response (At week 16): The Percentage of Participants With sPGA Response of 0 or 1 (At week 16): Arm 1: BMS-986165 55.6% (95% CI 47.4 to 63.7) vs Arm 2: Placebo 6.8% (95% CI 1 to 12.5) (met)

Result source: NCT04167462

zasocitinib

Developed by Takeda Pharmaceutical Company

Phase 3 in Psoriasissmall molecule
Reliable signal

NCT06108544 · Phase 3 · completed

This randomized, quadruple-blind, placebo- and active-controlled Phase 3 trial (n=1,108) in moderate-to-severe plaque psoriasis found that zasocitinib produced clear or almost-clear skin in 69.2% of patients at week 16, compared with 12.6% on placebo (p<0.001).

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Next expected readout: May 2027 · NCT07752108 (registry estimate)

Reported efficacy

Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI)-100 at Week 16: LATITUDE Atlas, PASI 100 at week 16: more than 35% of zasocitinib-treated patients achieved complete skin clearance (PASI 100), more than 2.5 times the response rate for deucravacitinib. (met)

Result source: NCT06973291

Results for Psoriasis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointdeucravacitinibzasocitinib
PASI 7553% vs 9.4%+43.6 vs placebowk 16 · n 511NCT03611751
9 other results
  • 58.4% vs 12.7% wk 16 · n 332 · Phase 3 · primary NCT03624127
  • 68.8% vs 8.1% wk 16 · n 144 · Phase 3 · primary NCT04167462
  • 53% vs 39.8% wk 16 · n 511 · Phase 3 · secondary NCT03611751
  • 58.4% vs 35.1% wk 16 · n 332 · Phase 3 · secondary NCT03624127
  • 75% vs 6.7% 12 mg QD · wk 12 · n 44 · Phase 2 · primary NCT02931838
  • 66.7% vs 6.7% 6 mg BID · wk 12 · n 45 · Phase 2 · primary NCT02931838
  • 9.1% vs 6.7% 3 mg QOD · wk 12 · n 44 · Phase 2 · primary NCT02931838
  • 38.6% vs 6.7% 3 mg QD · wk 12 · n 44 · Phase 2 · primary NCT02931838
  • 68.9% vs 6.7% 3 mg BID · wk 12 · n 45 · Phase 2 · primary NCT02931838
67.3% vs 5.8%+61.5 vs placebo30 mg · wk 12 · n 52NCT04999839
4 other results
  • 67.9% vs 5.8% 15 mg · wk 12 · n 53 · Phase 2 · primary NCT04999839
  • 44.2% vs 5.8% 5 mg · wk 12 · n 52 · Phase 2 · primary NCT04999839
  • 18% vs 5.8% 2 mg · wk 12 · n 50 · Phase 2 · primary NCT04999839
  • 75.7% vs 12.1% wk 16 · Phase 3 · primary NCT06088043
PASI 9027% vs 2.7%+24.3 vs placebowk 16 · n 511NCT03611751
2 other results
  • 35.5% vs 4.2% wk 16 · n 332 · Phase 3 · secondary NCT03624127
  • 38.2% vs 1.4% wk 16 · n 144 · Phase 3 · secondary NCT04167462
46.2% vs 0%+46.2 vs placebo30 mg · wk 12 · n 52NCT04999839
3 other results
  • 45.3% vs 0% 15 mg · wk 12 · n 53 · Phase 2 · secondary NCT04999839
  • 21.2% vs 0% 5 mg · wk 12 · n 52 · Phase 2 · secondary NCT04999839
  • 8% vs 0% 2 mg · wk 12 · n 50 · Phase 2 · secondary NCT04999839
PASI 10010.2% vs 1.2%+9 vs placebowk 16 · n 511NCT03611751
2 other results
  • 14.2% vs 0.6% wk 16 · n 332 · Phase 3 · secondary NCT03624127
  • 4.2% vs 0% wk 16 · n 144 · Phase 3 · secondary NCT04167462
32.7% vs 0%+32.7 vs placebo30 mg · wk 12 · n 52NCT04999839
3 other results
  • 15.1% vs 0% 15 mg · wk 12 · n 53 · Phase 2 · secondary NCT04999839
  • 9.6% vs 0% 5 mg · wk 12 · n 52 · Phase 2 · secondary NCT04999839
  • 2% vs 0% 2 mg · wk 12 · n 50 · Phase 2 · secondary NCT04999839
sPGA 0/149.5% vs 8.6%+40.9 vs placebowk 16 · n 511NCT03611751
11 other results
  • 53.6% vs 7.2% wk 16 · n 332 · Phase 3 · primary NCT03624127
  • 55.6% vs 6.8% wk 16 · n 144 · Phase 3 · primary NCT04167462
  • 49.5% vs 33.9% wk 16 · n 511 · Phase 3 · secondary NCT03611751
  • 53.6% vs 32.1% wk 16 · n 332 · Phase 3 · secondary NCT03624127
  • 75% vs 6.7% 12 mg QD · wk 12 · n 44 · Phase 2 · secondary NCT02931838
  • 64.4% vs 6.7% 6 mg BID · wk 12 · n 45 · Phase 2 · secondary NCT02931838
  • 20.5% vs 6.7% 3 mg QOD · wk 12 · n 44 · Phase 2 · secondary NCT02931838
  • 38.6% vs 6.7% 3 mg QD · wk 12 · n 44 · Phase 2 · secondary NCT02931838
  • 75.6% vs 6.7% 3 mg BID · wk 12 · n 45 · Phase 2 · secondary NCT02931838
  • 35.5% vs 8.2% wk 16 · n 107 · Phase 4 · secondary NCT05701995
  • 51% vs 4.3% wk 16 · n 96 · Phase 4 · secondary NCT05478499
51.9% vs 3.8%+48.1 vs placebo30 mg · wk 12 · n 52NCT04999839
5 other results
  • 49.1% vs 3.8% 15 mg · wk 12 · n 53 · Phase 2 · secondary NCT04999839
  • 26.9% vs 3.8% 5 mg · wk 12 · n 52 · Phase 2 · secondary NCT04999839
  • 10% vs 3.8% 2 mg · wk 12 · n 50 · Phase 2 · secondary NCT04999839
  • 69.2% vs 12.6% wk 16 · Phase 3 · primary NCT06108544
  • 71.4% vs 10.7% wk 16 · Phase 3 · primary NCT06088043
DLQI, change-10.2 vs -2.9−7.3 vs placebo12 mg QD · wk 12 · n 44NCT02931838
4 other results
  • -8.4 vs -2.9 6 mg BID · wk 12 · n 45 · Phase 2 · secondary NCT02931838
  • -3.8 vs -2.9 3 mg QOD · wk 12 · n 44 · Phase 2 · secondary NCT02931838
  • -6.1 vs -2.9 3 mg QD · wk 12 · n 44 · Phase 2 · secondary NCT02931838
  • -9.7 vs -2.9 3 mg BID · wk 12 · n 45 · Phase 2 · secondary NCT02931838
-8.9 vs -4.9−4 vs placebo30 mg · wk 12 · n 47NCT04999839
3 other results
  • -8.5 vs -4.9 15 mg · wk 12 · n 46 · Phase 2 · secondary NCT04999839
  • -7.9 vs -4.9 5 mg · wk 12 · n 47 · Phase 2 · secondary NCT04999839
  • -5.3 vs -4.9 2 mg · wk 12 · n 43 · Phase 2 · secondary NCT04999839

PASI 75

deucravacitinib
53% vs 9.4%+43.6 vs placebowk 16 · n 511NCT03611751
9 other results
  • 58.4% vs 12.7% wk 16 · n 332 · Phase 3 · primary NCT03624127
  • 68.8% vs 8.1% wk 16 · n 144 · Phase 3 · primary NCT04167462
  • 53% vs 39.8% wk 16 · n 511 · Phase 3 · secondary NCT03611751
  • 58.4% vs 35.1% wk 16 · n 332 · Phase 3 · secondary NCT03624127
  • 75% vs 6.7% 12 mg QD · wk 12 · n 44 · Phase 2 · primary NCT02931838
  • 66.7% vs 6.7% 6 mg BID · wk 12 · n 45 · Phase 2 · primary NCT02931838
  • 9.1% vs 6.7% 3 mg QOD · wk 12 · n 44 · Phase 2 · primary NCT02931838
  • 38.6% vs 6.7% 3 mg QD · wk 12 · n 44 · Phase 2 · primary NCT02931838
  • 68.9% vs 6.7% 3 mg BID · wk 12 · n 45 · Phase 2 · primary NCT02931838
zasocitinib
67.3% vs 5.8%+61.5 vs placebo30 mg · wk 12 · n 52NCT04999839
4 other results
  • 67.9% vs 5.8% 15 mg · wk 12 · n 53 · Phase 2 · primary NCT04999839
  • 44.2% vs 5.8% 5 mg · wk 12 · n 52 · Phase 2 · primary NCT04999839
  • 18% vs 5.8% 2 mg · wk 12 · n 50 · Phase 2 · primary NCT04999839
  • 75.7% vs 12.1% wk 16 · Phase 3 · primary NCT06088043

PASI 90

deucravacitinib
27% vs 2.7%+24.3 vs placebowk 16 · n 511NCT03611751
2 other results
  • 35.5% vs 4.2% wk 16 · n 332 · Phase 3 · secondary NCT03624127
  • 38.2% vs 1.4% wk 16 · n 144 · Phase 3 · secondary NCT04167462
zasocitinib
46.2% vs 0%+46.2 vs placebo30 mg · wk 12 · n 52NCT04999839
3 other results
  • 45.3% vs 0% 15 mg · wk 12 · n 53 · Phase 2 · secondary NCT04999839
  • 21.2% vs 0% 5 mg · wk 12 · n 52 · Phase 2 · secondary NCT04999839
  • 8% vs 0% 2 mg · wk 12 · n 50 · Phase 2 · secondary NCT04999839

PASI 100

deucravacitinib
10.2% vs 1.2%+9 vs placebowk 16 · n 511NCT03611751
2 other results
  • 14.2% vs 0.6% wk 16 · n 332 · Phase 3 · secondary NCT03624127
  • 4.2% vs 0% wk 16 · n 144 · Phase 3 · secondary NCT04167462
zasocitinib
32.7% vs 0%+32.7 vs placebo30 mg · wk 12 · n 52NCT04999839
3 other results
  • 15.1% vs 0% 15 mg · wk 12 · n 53 · Phase 2 · secondary NCT04999839
  • 9.6% vs 0% 5 mg · wk 12 · n 52 · Phase 2 · secondary NCT04999839
  • 2% vs 0% 2 mg · wk 12 · n 50 · Phase 2 · secondary NCT04999839

sPGA 0/1

deucravacitinib
49.5% vs 8.6%+40.9 vs placebowk 16 · n 511NCT03611751
11 other results
  • 53.6% vs 7.2% wk 16 · n 332 · Phase 3 · primary NCT03624127
  • 55.6% vs 6.8% wk 16 · n 144 · Phase 3 · primary NCT04167462
  • 49.5% vs 33.9% wk 16 · n 511 · Phase 3 · secondary NCT03611751
  • 53.6% vs 32.1% wk 16 · n 332 · Phase 3 · secondary NCT03624127
  • 75% vs 6.7% 12 mg QD · wk 12 · n 44 · Phase 2 · secondary NCT02931838
  • 64.4% vs 6.7% 6 mg BID · wk 12 · n 45 · Phase 2 · secondary NCT02931838
  • 20.5% vs 6.7% 3 mg QOD · wk 12 · n 44 · Phase 2 · secondary NCT02931838
  • 38.6% vs 6.7% 3 mg QD · wk 12 · n 44 · Phase 2 · secondary NCT02931838
  • 75.6% vs 6.7% 3 mg BID · wk 12 · n 45 · Phase 2 · secondary NCT02931838
  • 35.5% vs 8.2% wk 16 · n 107 · Phase 4 · secondary NCT05701995
  • 51% vs 4.3% wk 16 · n 96 · Phase 4 · secondary NCT05478499
zasocitinib
51.9% vs 3.8%+48.1 vs placebo30 mg · wk 12 · n 52NCT04999839
5 other results
  • 49.1% vs 3.8% 15 mg · wk 12 · n 53 · Phase 2 · secondary NCT04999839
  • 26.9% vs 3.8% 5 mg · wk 12 · n 52 · Phase 2 · secondary NCT04999839
  • 10% vs 3.8% 2 mg · wk 12 · n 50 · Phase 2 · secondary NCT04999839
  • 69.2% vs 12.6% wk 16 · Phase 3 · primary NCT06108544
  • 71.4% vs 10.7% wk 16 · Phase 3 · primary NCT06088043

DLQI, change

deucravacitinib
-10.2 vs -2.9−7.3 vs placebo12 mg QD · wk 12 · n 44NCT02931838
4 other results
  • -8.4 vs -2.9 6 mg BID · wk 12 · n 45 · Phase 2 · secondary NCT02931838
  • -3.8 vs -2.9 3 mg QOD · wk 12 · n 44 · Phase 2 · secondary NCT02931838
  • -6.1 vs -2.9 3 mg QD · wk 12 · n 44 · Phase 2 · secondary NCT02931838
  • -9.7 vs -2.9 3 mg BID · wk 12 · n 45 · Phase 2 · secondary NCT02931838
zasocitinib
-8.9 vs -4.9−4 vs placebo30 mg · wk 12 · n 47NCT04999839
3 other results
  • -8.5 vs -4.9 15 mg · wk 12 · n 46 · Phase 2 · secondary NCT04999839
  • -7.9 vs -4.9 5 mg · wk 12 · n 47 · Phase 2 · secondary NCT04999839
  • -5.3 vs -4.9 2 mg · wk 12 · n 43 · Phase 2 · secondary NCT04999839
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. deucravacitinib: 4 of 4 rows · zasocitinib: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricdeucravacitinib
Rows use multiple source trials
zasocitinib
Rows use multiple source trials
Dropout rate
0.2%BMS-986165a
NCT03611751 · Phase 3 · monotherapy
show 20 more results
—BMS-986165 (Week 0 up to Week 16)
NCT03611751 · Phase 3 · monotherapy
—BMS-986165 (Week 0 up to Week 52)
NCT03611751 · Phase 3 · monotherapy
0%BMS-986165
NCT03624127 · Phase 3 · monotherapy
—BMS-986165 Week 0 up to Week 16
NCT03624127 · Phase 3 · monotherapy
—BMS-986165 Week 0 up to Week 52
NCT03624127 · Phase 3 · monotherapy
9.6%Arm 1: BMS-986165
NCT04167462 · Phase 3 · monotherapy
—BMS-986165 Week 0 up to Week 52
NCT04167462 · Phase 3 · monotherapy
—BMS-986165 Week 16 up to Week 52
NCT04167462 · Phase 3 · monotherapy
—Active Treatment - Deucravacitinib
NCT05701995 · Phase 4 · registry result, not featured evidence
0.8%Deucravacitinib
NCT05701995 · Phase 4 · registry result, not featured evidence
—Placebo Controlled - Deucravacitin
NCT05701995 · Phase 4 · registry result, not featured evidence
—Active Treatment - Deucravacitinib
NCT05478499 · Phase 4 · registry result, not featured evidence
8.7%Deucravacitinib
NCT05478499 · Phase 4 · registry result, not featured evidence
—Placebo Controlled - Deucravacitin
NCT05478499 · Phase 4 · registry result, not featured evidence
8.1%6 mg QD
NCT03924427 · Phase 3 · registry result, not featured evidence
4.5%12 mg QD
NCT02931838 · Phase 2 · registry result, not featured evidence
13.3%6 mg BID
NCT02931838 · Phase 2 · registry result, not featured evidence
6.7%3 mg BID
NCT02931838 · Phase 2 · registry result, not featured evidence
18.2%3 mg QD
NCT02931838 · Phase 2 · registry result, not featured evidence
22.7%3 mg QOD
NCT02931838 · Phase 2 · registry result, not featured evidence
9.6%30 mga
NCT04999839 · Phase 2 · registry result, not featured evidence
show 3 more results
13.2%15 mg
NCT04999839 · Phase 2 · registry result, not featured evidence
13.5%5 mg
NCT04999839 · Phase 2 · registry result, not featured evidence
16%2 mg
NCT04999839 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
—BMS-986165a
NCT03611751 · Phase 3 · monotherapy
show 20 more results
—BMS-986165 (Week 0 up to Week 16)
NCT03611751 · Phase 3 · monotherapy
—BMS-986165 (Week 0 up to Week 52)
NCT03611751 · Phase 3 · monotherapy
—BMS-986165
NCT03624127 · Phase 3 · monotherapy
—BMS-986165 Week 0 up to Week 16
NCT03624127 · Phase 3 · monotherapy
—BMS-986165 Week 0 up to Week 52
NCT03624127 · Phase 3 · monotherapy
2.7%Arm 1: BMS-986165
NCT04167462 · Phase 3 · monotherapy
—BMS-986165 Week 0 up to Week 52
NCT04167462 · Phase 3 · monotherapy
—BMS-986165 Week 16 up to Week 52
NCT04167462 · Phase 3 · monotherapy
—Active Treatment - Deucravacitinib
NCT05701995 · Phase 4 · registry result, not featured evidence
—Deucravacitinib
NCT05701995 · Phase 4 · registry result, not featured evidence
—Placebo Controlled - Deucravacitin
NCT05701995 · Phase 4 · registry result, not featured evidence
—Active Treatment - Deucravacitinib
NCT05478499 · Phase 4 · registry result, not featured evidence
3.9%Deucravacitinib
NCT05478499 · Phase 4 · registry result, not featured evidence
—Placebo Controlled - Deucravacitin
NCT05478499 · Phase 4 · registry result, not featured evidence
5.4%6 mg QD
NCT03924427 · Phase 3 · registry result, not featured evidence
2.3%12 mg QD
NCT02931838 · Phase 2 · registry result, not featured evidence
6.7%6 mg BID
NCT02931838 · Phase 2 · registry result, not featured evidence
2.2%3 mg BID
NCT02931838 · Phase 2 · registry result, not featured evidence
4.5%3 mg QD
NCT02931838 · Phase 2 · registry result, not featured evidence
2.3%3 mg QOD
NCT02931838 · Phase 2 · registry result, not featured evidence
1.9%30 mga
NCT04999839 · Phase 2 · registry result, not featured evidence
show 3 more results
1.9%15 mg
NCT04999839 · Phase 2 · registry result, not featured evidence
1.9%5 mg
NCT04999839 · Phase 2 · registry result, not featured evidence
2%2 mg
NCT04999839 · Phase 2 · registry result, not featured evidence
Serious AEs
—BMS-986165a
NCT03611751 · Phase 3 · monotherapy
show 20 more results
1.6%BMS-986165 (Week 0 up to Week 16)
NCT03611751 · Phase 3 · monotherapy
2.9%BMS-986165 (Week 0 up to Week 52)
NCT03611751 · Phase 3 · monotherapy
—BMS-986165
NCT03624127 · Phase 3 · monotherapy
2.1%BMS-986165 Week 0 up to Week 16
NCT03624127 · Phase 3 · monotherapy
5.8%BMS-986165 Week 0 up to Week 52
NCT03624127 · Phase 3 · monotherapy
—Arm 1: BMS-986165
NCT04167462 · Phase 3 · monotherapy
2.7%BMS-986165 Week 0 up to Week 52
NCT04167462 · Phase 3 · monotherapy
0%BMS-986165 Week 16 up to Week 52
NCT04167462 · Phase 3 · monotherapy
4.9%Active Treatment - Deucravacitinib
NCT05701995 · Phase 4 · registry result, not featured evidence
—Deucravacitinib
NCT05701995 · Phase 4 · registry result, not featured evidence
2.5%Placebo Controlled - Deucravacitin
NCT05701995 · Phase 4 · registry result, not featured evidence
4.3%Active Treatment - Deucravacitinib
NCT05478499 · Phase 4 · registry result, not featured evidence
—Deucravacitinib
NCT05478499 · Phase 4 · registry result, not featured evidence
1%Placebo Controlled - Deucravacitin
NCT05478499 · Phase 4 · registry result, not featured evidence
6.8%6 mg QD
NCT03924427 · Phase 3 · registry result, not featured evidence
0%12 mg QD
NCT02931838 · Phase 2 · registry result, not featured evidence
0%6 mg BID
NCT02931838 · Phase 2 · registry result, not featured evidence
2.2%3 mg BID
NCT02931838 · Phase 2 · registry result, not featured evidence
2.3%3 mg QD
NCT02931838 · Phase 2 · registry result, not featured evidence
2.3%3 mg QOD
NCT02931838 · Phase 2 · registry result, not featured evidence
0%30 mga
NCT04999839 · Phase 2 · registry result, not featured evidence
show 3 more results
1.9%15 mg
NCT04999839 · Phase 2 · registry result, not featured evidence
0%5 mg
NCT04999839 · Phase 2 · registry result, not featured evidence
0%2 mg
NCT04999839 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
a
nasopharyngitis 10.8% (placebo 11.4%)
upper respiratory tract infection 4.9% (placebo 4.3%)
diarrhoea 4.7% (placebo 7.5%)
NCT03611751 · Phase 3 · monotherapy
show 15 more results
nasopharyngitis 16% (placebo 11.4%)
upper respiratory tract infection 8.9% (placebo 4.3%)
headache 5.4% (placebo 5.5%)
NCT03611751 · Phase 3 · monotherapy
nasopharyngitis 6.3% (placebo 4.2%)
upper respiratory tract infection 6.3% (placebo 3.6%)
headache 4.8% (placebo 3%)
NCT03624127 · Phase 3 · monotherapy
nasopharyngitis 18.1% (placebo 4.2%)
upper respiratory tract infection 9.4% (placebo 3.6%)
headache 6.6% (placebo 3%)
NCT03624127 · Phase 3 · monotherapy
upper respiratory tract infection 17.8% (placebo 18.9%)
mouth ulceration 7.5% (placebo 5.4%)
nasopharyngitis 6.8% (placebo 8.1%)
NCT04167462 · Phase 3 · monotherapy
psoriasis 11.8% (placebo 2.7%)
headache 5.9% (placebo 0%)
nasopharyngitis 5.9% (placebo 8.1%)
NCT04167462 · Phase 3 · monotherapy
covid-19 9.7% (placebo 4.1%)
upper respiratory tract infection 7.8% (placebo 2%)
nasopharyngitis 3.9% (placebo 4.1%)
NCT05701995 · Phase 4 · registry result, not featured evidence
acne 7.6% (placebo 4.1%)
nasopharyngitis 6.7% (placebo 4.1%)
covid-19 5.9% (placebo 4.1%)
NCT05701995 · Phase 4 · registry result, not featured evidence
nasopharyngitis 23.4% (placebo 17.8%)
covid-19 12.8% (placebo 8.9%)
upper respiratory tract infection 11.7% (placebo 6.7%)
NCT05478499 · Phase 4 · registry result, not featured evidence
nasopharyngitis 15.5% (placebo 17.8%)
upper respiratory tract infection 11.7% (placebo 6.7%)
acne 9.7% (placebo 2.2%)
NCT05478499 · Phase 4 · registry result, not featured evidence
6 mg QD
nasopharyngitis 31.1%
acne 9.5%
constipation 5.4%
NCT03924427 · Phase 3 · registry result, not featured evidence
12 mg QD
blood creatine phosphokinase increased 15.9% (placebo 2.2%)
acne 9.1% (placebo 0%)
diarrhoea 9.1% (placebo 4.4%)
NCT02931838 · Phase 2 · registry result, not featured evidence
6 mg BID
nasopharyngitis 15.6% (placebo 4.4%)
blood creatine phosphokinase increased 8.9% (placebo 2.2%)
upper respiratory tract infection 8.9% (placebo 2.2%)
NCT02931838 · Phase 2 · registry result, not featured evidence
3 mg BID
nasopharyngitis 11.1% (placebo 4.4%)
aphthous ulcer 6.7% (placebo 0%)
headache 6.7% (placebo 4.4%)
NCT02931838 · Phase 2 · registry result, not featured evidence
3 mg QD
nasopharyngitis 11.4% (placebo 4.4%)
headache 9.1% (placebo 4.4%)
psoriasis 6.8% (placebo 4.4%)
NCT02931838 · Phase 2 · registry result, not featured evidence
3 mg QOD
headache 9.1% (placebo 4.4%)
nausea 9.1% (placebo 4.4%)
blood immunoglobulin e increased 6.8% (placebo 2.2%)
NCT02931838 · Phase 2 · registry result, not featured evidence
30 mga
covid-19 13.5% (placebo 1.9%)
blood creatine phosphokinase increased 5.8% (placebo 3.8%)
dermatitis acneiform 5.8% (placebo 0%)
NCT04999839 · Phase 2 · registry result, not featured evidence
show 3 more results
15 mg
covid-19 11.3% (placebo 1.9%)
acne 5.7% (placebo 0%)
blood creatine phosphokinase increased 5.7% (placebo 3.8%)
NCT04999839 · Phase 2 · registry result, not featured evidence
5 mg
covid-19 7.7% (placebo 1.9%)
lymphocyte count decreased 5.8% (placebo 0%)
blood creatine phosphokinase increased 3.8% (placebo 3.8%)
NCT04999839 · Phase 2 · registry result, not featured evidence
2 mg
covid-19 12% (placebo 1.9%)
alanine aminotransferase increased 6% (placebo 0%)
diarrhoea 6% (placebo 1.9%)
NCT04999839 · Phase 2 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

deucravacitinib

sPGA (0 15.7% (n=511) vs 1.2% (n=255) placebo @ 16wk
responder rate · % of participants
NCT03611751 · Phase 3 · monotherapy · converted to % from 80 Participants as posted
show 2 more results
17.5% (n=332) vs 0.6% (n=166) placebo @ 16wk*
NCT03624127 · Phase 3 · monotherapy · converted to % from 58 Participants as posted
13.9% (n=144) vs 0% (n=74) placebo @ 16wk
NCT04167462 · Phase 3 · monotherapy
PSSD Symptom -28.9 vs -4.2 placebo score @ 16wk
absolute change · score
NCT03611751 · Phase 3 · monotherapy
show 2 more results
-29.4 vs -22.8 Apremilast score @ 16wk
NCT03624127 · Phase 3 · monotherapy
-29.4 vs -1.8 placebo score @ 16wk
NCT04167462 · Phase 3 · monotherapy
PSSD Symptom Score 0 7.5% (n=466) vs 1.3% (n=238) placebo @ 16wk
event count · % of participants
NCT03611751 · Phase 3 · monotherapy · converted to % from 35 Participants as posted
show 1 more result
7.9% (n=305) vs 0.7% (n=149) placebo @ 16wk*
NCT03624127 · Phase 3 · monotherapy · converted to % from 24 Participants as posted
Ss-PGA 0/1 59.7% (n=305) vs 17.3% (n=173) placebo @ 16wk
responder rate · % of participants
NCT03611751 · Phase 3 · monotherapy · converted to % from 182 Participants as posted
show 2 more results
70.3% (n=209) vs 17.4% (n=121) placebo @ 16wk*
NCT03624127 · Phase 3 · monotherapy · converted to % from 147 Participants as posted
62.9% (n=105) vs 9.8% (n=51) placebo @ 16wk
NCT04167462 · Phase 3 · monotherapy
DLQI 0/1 37.6% (n=495) vs 9.8% (n=246) placebo @ 16wk
responder rate · % of participants
NCT03611751 · Phase 3 · monotherapy · converted to % from 186 Participants as posted
show 2 more results
41% (n=322) vs 10.6% (n=160) placebo @ 16wk*
NCT03624127 · Phase 3 · monotherapy · converted to % from 132 Participants as posted
36.4% (n=140) vs 11.6% (n=69) placebo @ 16wk
NCT04167462 · Phase 3 · monotherapy
PGA-F 0/1 20.3% (n=69) vs 7.9% (n=38) placebo @ 16wk
responder rate · % of participants
NCT03611751 · Phase 3 · monotherapy · converted to % from 14 Participants as posted
show 2 more results
20.9% (n=43) vs 8.8% (n=34) placebo @ 16wk*
NCT03624127 · Phase 3 · monotherapy · converted to % from 9 Participants as posted
19.6% (n=46) vs 4.2% (n=24) placebo @ 16wk
NCT04167462 · Phase 3 · monotherapy
Pp-PGA 0/1 46.2% (n=39) vs 23.5% (n=17) placebo @ 16wk
responder rate · % of participants
NCT03611751 · Phase 3 · monotherapy · converted to % from 18 Participants as posted
show 1 more result
66.7% (n=15) vs 0% (n=7) placebo @ 16wk
NCT04167462 · Phase 3 · monotherapy
Time to Relapse Median NA vs NA placebo months
time to event · months
NCT03611751 · Phase 3 · monotherapy
PSSD Symptom Score 0 4.9% (n=142) vs 1.4% (n=73) placebo @ 16wk
responder rate · % of participants
NCT04167462 · Phase 3 · monotherapy
DLQI 0/1 33.3% (n=120) vs 6.7% (n=60) placebo @ 16wk
responder rate · % of participants
Full Analysis Set
NCT05701995 · Phase 4 · registry result, not featured evidence
DLQI 4-point Improvement 72.5% (n=120) vs 53.3% (n=60) placebo @ 16wk
responder rate · % of participants
Full Analysis Set
NCT05701995 · Phase 4 · registry result, not featured evidence
Itch NRS -3.8 vs -1.8 placebo score @ 16wk
absolute change · score
Full Analysis Set
NCT05701995 · Phase 4 · registry result, not featured evidence

+ 6 further endpoints in the CSV export.

Psoriatic Arthritis

Shared mechanism: TYK2 · full Psoriatic Arthritis pipeline

deucravacitinib · Sotyktu

Marketed by Bristol-Myers Squibb

Approved in Psoriatic Arthritissmall molecule
Reliable signal

NCT04908202 · Phase 3 · active, not recruiting

This was a large (670-patient), randomized, quadruple-blinded, placebo-controlled trial with the primary endpoint being ACR20 response, a validated hard clinical measure of joint disease activity. The result was statistically significant and favored deucravacitinib (54.2% vs 34.1% on placebo, p<0.0001), meeting all criteria for the highest evidence tier.

Next expected readout: December 2027 · NCT07280702 (registry estimate)

Reported efficacy

Number of Participants Meeting American College of Rheumatology (ACR) 20 at Week 16: POETYK PsA-2 (NCT04908189), primary endpoint ACR20 at week 16: deucravacitinib 54.2% vs placebo 39.4%; p=0.0002 (met)

Result source: NCT04908189

zasocitinib

Developed by Takeda Pharmaceutical Company

Phase 3 in Psoriatic Arthritissmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: May 2027 · NCT06671496 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Psoriatic Arthritis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointdeucravacitinibzasocitinib
ACR2052.9% vs 31.8%+21.1 vs placebo6 mg · wk 16 · n 70NCT03881059
1 other result
  • 62.7% vs 31.8% 12 mg · wk 16 · n 67 · Phase 2 · primary NCT03881059
35.2% vs 29.2%+6 vs placebowk 12 · n 71NCT05153148
2 other results
  • 53.3% vs 29.2% wk 12 · n 75 · Phase 2 · primary NCT05153148
  • 54.2% vs 29.2% wk 12 · n 72 · Phase 2 · primary NCT05153148
ACR5024.3% vs 10.6%+13.7 vs placebo6 mg · wk 16 · n 70NCT03881059
1 other result
  • 32.8% vs 10.6% 12 mg · wk 16 · n 67 · Phase 2 · secondary NCT03881059
15.5% vs 9.7%+5.8 vs placebowk 12 · n 71NCT05153148
2 other results
  • 26.7% vs 9.7% wk 12 · n 75 · Phase 2 · secondary NCT05153148
  • 26.4% vs 9.7% wk 12 · n 72 · Phase 2 · secondary NCT05153148
PASI 7542.4% vs 20.4%+22 vs placebo6 mg · wk 16 · n 59NCT03881059
1 other result
  • 59.6% vs 20.4% 12 mg · wk 16 · n 52 · Phase 2 · secondary NCT03881059
25.6% vs 15.4%+10.2 vs placebowk 12 · n 39NCT05153148
2 other results
  • 28.3% vs 15.4% wk 12 · n 46 · Phase 2 · secondary NCT05153148
  • 45.7% vs 15.4% wk 12 · n 46 · Phase 2 · secondary NCT05153148
Minimal disease activity22.9% vs 7.6%+15.3 vs placebo6 mg · wk 16 · n 70NCT03881059
1 other result
  • 23.9% vs 7.6% 12 mg · wk 16 · n 67 · Phase 2 · secondary NCT03881059
18.3% vs 12.5%+5.8 vs placebowk 12 · n 71NCT05153148
2 other results
  • 28% vs 12.5% wk 12 · n 75 · Phase 2 · secondary NCT05153148
  • 29.2% vs 12.5% wk 12 · n 72 · Phase 2 · secondary NCT05153148
HAQ-DI, change-0.4 vs -0.1−0.3 vs placebo6 mg · wk 16 · n 70NCT03881059
1 other result
  • -0.4 vs -0.1 12 mg · wk 16 · n 67 · Phase 2 · secondary NCT03881059
-0.3 vs -0.2−0.1 vs placebowk 12 · n 66NCT05153148
2 other results
  • -0.3 vs -0.2 wk 12 · n 64 · Phase 2 · secondary NCT05153148
  • -0.3 vs -0.2 wk 12 · n 63 · Phase 2 · secondary NCT05153148

ACR20

deucravacitinib
52.9% vs 31.8%+21.1 vs placebo6 mg · wk 16 · n 70NCT03881059
1 other result
  • 62.7% vs 31.8% 12 mg · wk 16 · n 67 · Phase 2 · primary NCT03881059
zasocitinib
35.2% vs 29.2%+6 vs placebowk 12 · n 71NCT05153148
2 other results
  • 53.3% vs 29.2% wk 12 · n 75 · Phase 2 · primary NCT05153148
  • 54.2% vs 29.2% wk 12 · n 72 · Phase 2 · primary NCT05153148

ACR50

deucravacitinib
24.3% vs 10.6%+13.7 vs placebo6 mg · wk 16 · n 70NCT03881059
1 other result
  • 32.8% vs 10.6% 12 mg · wk 16 · n 67 · Phase 2 · secondary NCT03881059
zasocitinib
15.5% vs 9.7%+5.8 vs placebowk 12 · n 71NCT05153148
2 other results
  • 26.7% vs 9.7% wk 12 · n 75 · Phase 2 · secondary NCT05153148
  • 26.4% vs 9.7% wk 12 · n 72 · Phase 2 · secondary NCT05153148

PASI 75

deucravacitinib
42.4% vs 20.4%+22 vs placebo6 mg · wk 16 · n 59NCT03881059
1 other result
  • 59.6% vs 20.4% 12 mg · wk 16 · n 52 · Phase 2 · secondary NCT03881059
zasocitinib
25.6% vs 15.4%+10.2 vs placebowk 12 · n 39NCT05153148
2 other results
  • 28.3% vs 15.4% wk 12 · n 46 · Phase 2 · secondary NCT05153148
  • 45.7% vs 15.4% wk 12 · n 46 · Phase 2 · secondary NCT05153148

Minimal disease activity

deucravacitinib
22.9% vs 7.6%+15.3 vs placebo6 mg · wk 16 · n 70NCT03881059
1 other result
  • 23.9% vs 7.6% 12 mg · wk 16 · n 67 · Phase 2 · secondary NCT03881059
zasocitinib
18.3% vs 12.5%+5.8 vs placebowk 12 · n 71NCT05153148
2 other results
  • 28% vs 12.5% wk 12 · n 75 · Phase 2 · secondary NCT05153148
  • 29.2% vs 12.5% wk 12 · n 72 · Phase 2 · secondary NCT05153148

HAQ-DI, change

deucravacitinib
-0.4 vs -0.1−0.3 vs placebo6 mg · wk 16 · n 70NCT03881059
1 other result
  • -0.4 vs -0.1 12 mg · wk 16 · n 67 · Phase 2 · secondary NCT03881059
zasocitinib
-0.3 vs -0.2−0.1 vs placebowk 12 · n 66NCT05153148
2 other results
  • -0.3 vs -0.2 wk 12 · n 64 · Phase 2 · secondary NCT05153148
  • -0.3 vs -0.2 wk 12 · n 63 · Phase 2 · secondary NCT05153148
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
2 other shared endpoints and safety

Coverage. deucravacitinib: 6 of 6 rows · zasocitinib: 6 of 6 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricdeucravacitinibzasocitinib
ACR70
responder rate · % of participants
14.3% (n=70) vs 1.5% (n=66) placebo @ 16wk6 mga,b,c,d
NCT03881059 · Phase 2 · registry result, not featured evidence
show 1 more dose
19.4% (n=67) vs 1.5% (n=66) placebo @ 16wk12 mg
NCT03881059 · Phase 2 · registry result, not featured evidence
13.9% (n=72) vs 5.6% (n=72) placebo @ 12wka,b,c,d
NCT05153148 · Phase 2 · registry result, not featured evidence
show 2 more doses
8.5% (n=71) vs 5.6% (n=72) placebo @ 12wk
NCT05153148 · Phase 2 · registry result, not featured evidence
14.7% (n=75) vs 5.6% (n=72) placebo @ 12wk
NCT05153148 · Phase 2 · registry result, not featured evidence
DAPSA
absolute change · score
-23.2 vs -13.3 placebo score @ 16wk6 mga,b,c,d
NCT03881059 · Phase 2 · registry result, not featured evidence
show 1 more dose
-25.6 vs -13.3 placebo score @ 16wk12 mg
NCT03881059 · Phase 2 · registry result, not featured evidence
-16.79 vs -11.56 placebo score @ 12wka,b,c,d
NCT05153148 · Phase 2 · registry result, not featured evidence
show 2 more doses
-15.3 vs -11.56 placebo score @ 12wk
NCT05153148 · Phase 2 · registry result, not featured evidence
-17.99 vs -11.56 placebo score @ 12wk
NCT05153148 · Phase 2 · registry result, not featured evidence
Dropout rate
10%6 mge
NCT03881059 · Phase 2 · registry result, not featured evidence
show 7 more results
—6 mg
NCT03881059 · Phase 2 · registry result, not featured evidence
—6 mg QD
NCT03881059 · Phase 2 · registry result, not featured evidence
—6 mg QD
NCT03881059 · Phase 2 · registry result, not featured evidence
11.9%12 mg
NCT03881059 · Phase 2 · registry result, not featured evidence
—12 mg
NCT03881059 · Phase 2 · registry result, not featured evidence
—12 mg QD
NCT03881059 · Phase 2 · registry result, not featured evidence
—12 mg QD
NCT03881059 · Phase 2 · registry result, not featured evidence
21.1%NDI-034858 High Dosee
NCT05153148 · Phase 2 · registry result, not featured evidence
show 2 more results
13.2%NDI-034858 Low Dose
NCT05153148 · Phase 2 · registry result, not featured evidence
16.7%NDI-034858 Medium Dose
NCT05153148 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
4.3%6 mge
NCT03881059 · Phase 2 · registry result, not featured evidence
show 7 more results
—6 mg
NCT03881059 · Phase 2 · registry result, not featured evidence
—6 mg QD
NCT03881059 · Phase 2 · registry result, not featured evidence
—6 mg QD
NCT03881059 · Phase 2 · registry result, not featured evidence
6%12 mg
NCT03881059 · Phase 2 · registry result, not featured evidence
—12 mg
NCT03881059 · Phase 2 · registry result, not featured evidence
—12 mg QD
NCT03881059 · Phase 2 · registry result, not featured evidence
—12 mg QD
NCT03881059 · Phase 2 · registry result, not featured evidence
6.6%NDI-034858 High Dosee
NCT05153148 · Phase 2 · registry result, not featured evidence
show 2 more results
0%NDI-034858 Low Dose
NCT05153148 · Phase 2 · registry result, not featured evidence
3.8%NDI-034858 Medium Dose
NCT05153148 · Phase 2 · registry result, not featured evidence
Serious AEs
—6 mge
NCT03881059 · Phase 2 · registry result, not featured evidence
show 7 more results
7.7%6 mg
NCT03881059 · Phase 2 · registry result, not featured evidence
0%6 mg QD
NCT03881059 · Phase 2 · registry result, not featured evidence
6.4%6 mg QD
NCT03881059 · Phase 2 · registry result, not featured evidence
—12 mg
NCT03881059 · Phase 2 · registry result, not featured evidence
0%12 mg
NCT03881059 · Phase 2 · registry result, not featured evidence
0%12 mg QD
NCT03881059 · Phase 2 · registry result, not featured evidence
9.5%12 mg QD
NCT03881059 · Phase 2 · registry result, not featured evidence
2.8%NDI-034858 High Dosee
NCT05153148 · Phase 2 · registry result, not featured evidence
show 2 more results
5.6%NDI-034858 Low Dose
NCT05153148 · Phase 2 · registry result, not featured evidence
4%NDI-034858 Medium Dose
NCT05153148 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
6 mge
aspartate aminotransferase increased 15.4% (placebo 0%)
headache 15.4% (placebo 9.1%)
hypertension 15.4% (placebo 0%)
NCT03881059 · Phase 2 · registry result, not featured evidence
show 5 more results
6 mg QD
bronchitis 10% (placebo 0%)
diarrhoea 10% (placebo 0%)
dizziness 10% (placebo 0%)
NCT03881059 · Phase 2 · registry result, not featured evidence
6 mg QD
headache 12.8% (placebo 9.1%)
nasopharyngitis 12.8% (placebo 0%)
bronchitis 6.4% (placebo 0%)
NCT03881059 · Phase 2 · registry result, not featured evidence
12 mg
pyrexia 18.8% (placebo 0%)
alanine aminotransferase increased 12.5% (placebo 0%)
aphthous ulcer 12.5% (placebo 0%)
NCT03881059 · Phase 2 · registry result, not featured evidence
12 mg QD
blood pressure increased 11.1% (placebo 0%)
dizziness 11.1% (placebo 0%)
furuncle 11.1% (placebo 0%)
NCT03881059 · Phase 2 · registry result, not featured evidence
12 mg QD
nasopharyngitis 26.2% (placebo 0%)
covid-19 11.9% (placebo 0%)
rash 9.5% (placebo 0%)
NCT03881059 · Phase 2 · registry result, not featured evidence
e
nasopharyngitis 9.7% (placebo 4.2%)
upper respiratory tract infection 9.7% (placebo 2.8%)
aphthous ulcer 8.3% (placebo 0%)
NCT05153148 · Phase 2 · registry result, not featured evidence
show 2 more results
upper respiratory tract infection 11.3% (placebo 2.8%)
nasopharyngitis 8.5% (placebo 4.2%)
rash 4.2% (placebo 0%)
NCT05153148 · Phase 2 · registry result, not featured evidence
nasopharyngitis 9.3% (placebo 4.2%)
headache 8% (placebo 4.2%)
rash 8% (placebo 0%)
NCT05153148 · Phase 2 · registry result, not featured evidence

Notes

  1. aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  2. bPopulation comparability has not been reviewed for both studies.
  3. cTreatment context has not been resolved for both arms.
  4. dAssessment timepoints differ: 16 weeks versus 12 weeks.
  5. ePopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

deucravacitinib

SF-36 PCS 5.6 vs 2.3 placebo score @ 16wk6 mg
absolute change · score
NCT03881059 · Phase 2 · registry result, not featured evidence
show 1 more result
5.8 vs 2.3 placebo score @ 16wk12 mg
NCT03881059 · Phase 2 · registry result, not featured evidence
DAS28 Low Disease Activity 37.1% (n=70) vs 22.7% (n=66) placebo @ 16wk6 mg
absolute value · percentage points
NCT03881059 · Phase 2 · registry result, not featured evidence
show 1 more result
43.3% (n=67) vs 22.7% (n=66) placebo @ 16wk12 mg
NCT03881059 · Phase 2 · registry result, not featured evidence
DAS28 (CRP) Remission 24.3% (n=70) vs 6.1% (n=66) placebo @ 16wk6 mg
responder rate · % of participants
NCT03881059 · Phase 2 · registry result, not featured evidence
show 1 more result
25.4% (n=67) vs 6.1% (n=66) placebo @ 16wk12 mg
NCT03881059 · Phase 2 · registry result, not featured evidence
DAS28-CRP -1.7 vs -0.9 placebo score @ 16wk6 mg
absolute change · score
NCT03881059 · Phase 2 · registry result, not featured evidence
show 1 more result
-1.7 vs -0.9 placebo score @ 16wk12 mg
NCT03881059 · Phase 2 · registry result, not featured evidence
Dactylitis -2 vs -1.8 placebo Digits with dactylitis @ 16wk6 mg
absolute change · Digits with dactylitis
NCT03881059 · Phase 2 · registry result, not featured evidence
show 1 more result
-2.5 vs -1.8 placebo Digits with dactylitis @ 16wk12 mg
NCT03881059 · Phase 2 · registry result, not featured evidence
Leeds Dactylitis Index -41.8 vs -28.3 placebo score @ 16wk6 mg
absolute change · score
NCT03881059 · Phase 2 · registry result, not featured evidence
show 1 more result
-44.5 vs -28.3 placebo score @ 16wk12 mg
NCT03881059 · Phase 2 · registry result, not featured evidence
Dactylitis Resolution 76.7% (n=30) vs 60% (n=25) placebo @ 16wk6 mg
absolute value · percentage points
NCT03881059 · Phase 2 · registry result, not featured evidence
show 1 more result
79.2% (n=24) vs 60% (n=25) placebo @ 16wk12 mg
NCT03881059 · Phase 2 · registry result, not featured evidence
Leeds Enthesitis Index -1.5 vs -1.2 placebo score @ 16wk6 mg
absolute change · score
NCT03881059 · Phase 2 · registry result, not featured evidence
show 1 more result
-1.7 vs -1.2 placebo score @ 16wk12 mg
NCT03881059 · Phase 2 · registry result, not featured evidence
SPARCC Enthesitis Index -2.9 vs -1.2 placebo score @ 16wk6 mg
absolute change · score
NCT03881059 · Phase 2 · registry result, not featured evidence
show 1 more result
-3.1 vs -1.2 placebo score @ 16wk12 mg
NCT03881059 · Phase 2 · registry result, not featured evidence
Enthesitis Resolution 51.3% (n=39) vs 22.6% (n=31) placebo @ 16wk6 mg
absolute value · percentage points
NCT03881059 · Phase 2 · registry result, not featured evidence
show 3 more results
51.2% (n=43) vs 17.6% (n=34) placebo @ 16wk6 mg
NCT03881059 · Phase 2 · registry result, not featured evidence
50% (n=26) vs 22.6% (n=31) placebo @ 16wk12 mg
NCT03881059 · Phase 2 · registry result, not featured evidence
41.2% (n=34) vs 17.6% (n=34) placebo @ 16wk12 mg
NCT03881059 · Phase 2 · registry result, not featured evidence
PGA-F 0/1 21.4% (n=14) vs 0% (n=12) placebo @ 16wk6 mg
responder rate · % of participants
NCT03881059 · Phase 2 · registry result, not featured evidence
show 1 more result
50% (n=20) vs 0% (n=12) placebo @ 16wk12 mg
NCT03881059 · Phase 2 · registry result, not featured evidence
PASDAS -2 vs -1.1 placebo score @ 16wk6 mg
absolute change · score
NCT03881059 · Phase 2 · registry result, not featured evidence
show 1 more result
-2.1 vs -1.1 placebo score @ 16wk12 mg
NCT03881059 · Phase 2 · registry result, not featured evidence

+ 8 further endpoints in the CSV export.

zasocitinib

Tender Joint Count -7.6 vs -5.9 placebo tender joints @ 12wk
absolute change · tender joints
NCT05153148 · Phase 2 · registry result, not featured evidence
show 2 more results
-8.9 vs -5.9 placebo tender joints @ 12wk
NCT05153148 · Phase 2 · registry result, not featured evidence
-8.3 vs -5.9 placebo tender joints @ 12wk
NCT05153148 · Phase 2 · registry result, not featured evidence
Swollen Joint Count -4.8 vs -3.9 placebo swollen joints @ 12wk
absolute change · swollen joints
NCT05153148 · Phase 2 · registry result, not featured evidence
show 2 more results
-5 vs -3.9 placebo swollen joints @ 12wk
NCT05153148 · Phase 2 · registry result, not featured evidence
-5 vs -3.9 placebo swollen joints @ 12wk
NCT05153148 · Phase 2 · registry result, not featured evidence
Patient Global Assessment -12.9 vs -11.1 placebo mm @ 12wk
absolute change · mm
NCT05153148 · Phase 2 · registry result, not featured evidence
show 2 more results
-20.2 vs -11.1 placebo mm @ 12wk
NCT05153148 · Phase 2 · registry result, not featured evidence
-19.8 vs -11.1 placebo mm @ 12wk
NCT05153148 · Phase 2 · registry result, not featured evidence
Patient Assessment of Arthritis Pain -13 vs -12.1 placebo mm @ 12wk
absolute change · mm
NCT05153148 · Phase 2 · registry result, not featured evidence
show 2 more results
-18.8 vs -12.1 placebo mm @ 12wk
NCT05153148 · Phase 2 · registry result, not featured evidence
-18.4 vs -12.1 placebo mm @ 12wk
NCT05153148 · Phase 2 · registry result, not featured evidence
Physician Global Assessment -29.6 vs -20.7 placebo mm @ 12wk
absolute change · mm
NCT05153148 · Phase 2 · registry result, not featured evidence
show 2 more results
-31.3 vs -20.7 placebo mm @ 12wk
NCT05153148 · Phase 2 · registry result, not featured evidence
-31.6 vs -20.7 placebo mm @ 12wk
NCT05153148 · Phase 2 · registry result, not featured evidence
Dactylitis -0.8 vs -2.1 placebo count @ 12wk
absolute change · count
NCT05153148 · Phase 2 · registry result, not featured evidence
show 2 more results
-2 vs -2.1 placebo count @ 12wk
NCT05153148 · Phase 2 · registry result, not featured evidence
-1.9 vs -2.1 placebo count @ 12wk
NCT05153148 · Phase 2 · registry result, not featured evidence
LEI -1.4 vs -0.9 placebo score @ 12wk
absolute change · score
NCT05153148 · Phase 2 · registry result, not featured evidence
show 2 more results
-1.6 vs -0.9 placebo score @ 12wk
NCT05153148 · Phase 2 · registry result, not featured evidence
-1 vs -0.9 placebo score @ 12wk
NCT05153148 · Phase 2 · registry result, not featured evidence
PGA 0-1 20.4% (n=54) vs 15.8% (n=57) placebo @ 12wk
responder rate · % of participants
NCT05153148 · Phase 2 · registry result, not featured evidence
show 2 more results
20.6% (n=63) vs 15.8% (n=57) placebo @ 12wk
NCT05153148 · Phase 2 · registry result, not featured evidence
32.8% (n=58) vs 15.8% (n=57) placebo @ 12wk
NCT05153148 · Phase 2 · registry result, not featured evidence

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: deucravacitinib's landscape · zasocitinib's landscape